UK markets open in 6 hours 56 minutes

Bellerophon Therapeutics, Inc. (0HMP.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
0.0551+0.0008 (+1.47%)
At close: 02:30PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.69
52-week change 3-99.20%
S&P500 52-week change 326.49%
52-week high 312.3500
52-week low 30.0000
50-day moving average 30.2924
200-day moving average 33.5448

Share statistics

Avg vol (3-month) 321.22k
Avg vol (10-day) 322.84k
Shares outstanding 5N/A
Implied shares outstanding 6N/A
Float 810.2M
% held by insiders 115.03%
% held by institutions 18.75%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 20.066667:1
Last split date 310 Feb 2020

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin -164.06%
Operating margin (ttm)-195.76%

Management effectiveness

Return on assets (ttm)-78.47%
Return on equity (ttm)-165.96%

Income statement

Revenue (ttm)5.64M
Revenue per share (ttm)0.51
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -11.04M
Net income avi to common (ttm)-9.25M
Diluted EPS (ttm)-1.8850
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)4.38M
Total cash per share (mrq)0.36
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)3.96
Book value per share (mrq)0.30

Cash flow statement

Operating cash flow (ttm)-12.34M
Levered free cash flow (ttm)-9.7M